Katie Bodner Spielberg is a Principal at 5AM Ventures, a company pursuing investments in advanced life science innovations.
Katie’s previous research spanned applying synthetic biology to cancer diagnostics, HIV vaccination, muscular dystrophy and biologics pharmaceutical production resulting in a publication and patent. She co-founded the Massachusetts Institute of Technology (MIT)’s first biotechnology student initiative. Katie’s work on bringing DNA computing to mammalian cells led to a gold medal for MIT’s iGEM team, a global undergraduate competition in synthetic biology.
As an Amgen Scholar, Katie developed a programmable, RNA platform for use as a vaccine for HIV and a therapeutic for Duchenne muscular dystrophy. She won the U.S. Biologics Technical Development Outstanding Student Award and interned at Genentech.
As a Hertz-Draper PhD student in bioengineering at Stanford, Katie focused on applying systems biology to improve drug development.
